Tanay Shah

Tanay Shah


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAnanda M. Rodilla
Ananda M. Rodilla
STSooyun Caroline Tavolacci
Sooyun Caroline Tavolacci
JCJazz Cagan
Jazz Cagan
TSTanay Shah
Tanay Shah
SMSandeep Mittan
Sandeep Mittan
FHFred R. Hirsch
Fred R. Hirsch
In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and mortality associated with it. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung cancer have been prioritized for COVID-19 vaccinations, primary and booster doses. Despite this, the pivotal clinical trials did not include these patients, which leaves open questions regarding vaccine efficacy and humoral immune response. This review outlines the findings of recent investigations into the humoral responses of lung cancer patients to COVID-19 vaccination, particularly the primary doses and first boost.